MarketPulse

Skyrizi

2 articles
BenzingaBenzinga··Vandana Singh

J&J and Protagonist Win FDA Approval for Oral Psoriasis Drug, Challenging AbbVie's Market Dominance

FDA approves Icotyde for psoriasis, triggering $50M payment to Protagonist. Market reacts with AbbVie stock falling 5.20% amid competitive pressure.
JNJABBVPTGXFDA approvalplaque psoriasis
BenzingaBenzinga··Vandana Singh

AbbVie's Skyrizi Posts Strong Remission Data, Challenges J&J in Crohn's Market

AbbVie's Skyrizi achieved 55% remission rate in Crohn's patients versus 30% placebo, strengthening competitive positioning against Johnson & Johnson's Tremfya.
JNJABBVimmunologyCrohn's disease